Overview
Overview
5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels[1][2]. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency[3]. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 50 mg via
- Category
- Weight Loss
- Routes
- oral, subcutaneous
Mechanism
5-Amino-1MQ
Mechanism of action
Mechanism of action
5-Amino-1MQ blocks one enzyme: NNMT (nicotinamide N-methyltransferase). That single block sets off a chain of changes inside fat cells. Here is the plain-English version. Your body uses a form of vitamin B3 called nicotinamide to build NAD+ , the energy currency that powers mitochondria and many cell-repair processes. NNMT is an enzyme that grabs nicotinamide and methylates it, turning it into a waste product called 1-MNA that gets cleared from the body. In obesity, NNMT activity is unusually high in fat cells, which means a lot of nicotinamide gets thrown out before it can be turned into NAD+. 5-Amino-1MQ stops that waste step. With NNMT blocked, nicotinamide stays in the cell, NAD+ levels climb, and fat cells start burning more fuel instead of storing it. Researchers also observed shifts in glucose uptake and sirtuin activity (the SIRT1 longevity protein family) when NNMT was blocked. In 3T3-L1 mouse fat cells, 30 µM of 5-Amino-1MQ for 24 hours strongly lowered 1-MNA levels — direct proof of NNMT inhibition (Neelakantan et al., Biochemical Pharmacology, 2018). The same study showed that NAD+ and S-adenosyl-methionine (SAM) both went up after NNMT inhibition. LC-MS/MS measurements confirmed both cofactors rose. In diet-induced obese mice, 11 days of 5-Amino-1MQ (subcutaneous, around 34 mg/kg/day) reduced body weight, total fat mass, and plasma cholesterol with no drop in food intake or lean mass. A follow-up 28-day study (Babula et al., 2024) extended the finding: 5-Amino-1MQ dose-dependently limited body weight and fat mass gain without changing food intake, and it improved liver markers in obese mice.
Key research findings
- 01
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme studied in adipocyte and metabolic regulation (mechanistic / in vitro).
- 02
In preclinical work, NNMT inhibition with 5-amino-1MQ was associated with reduced fat accumulation and altered metabolic parameters in diet-induced obese mice (animal model; Biochemical Pharmacology, 2018).
- 03
Proposed mechanisms involve effects on cellular NAD+ and methylation metabolism in adipose tissue (in vitro / mechanistic).
- 04
It is a small molecule, not a peptide, and acts intracellularly rather than on cell-surface receptors (mechanistic).
- 05
No human clinical trials are established; the evidence base is preclinical.
Primary source: Cell-culture (3T3-L1 adipocytes): 5-Amino-1MQ at 30 µM strongly reduced 1-MNA levels in mouse fat cells, confirming NNMT inhibition (Neelakantan et al., Biochemical Pharmacology, 2018). Rodent (diet-induced obesity, 11 days): Subcutaneous 5-Amino-1MQ at roughly 34 mg/kg/day reduced body weight and white adipose mass without changing food intake or lean mass. Rodent (diet-induced obesity, 28 days): Babula et al. (2024) confirmed dose-dependent body-weight and fat-mass reduction over a longer treatment window, with improvements in fatty-liver markers. Rodent (lean diet combination): Sampson et al. (Scientific Reports, 2021) reported that NNMT inhibition plus a lean-diet substitution lowered body weight, fat mass, and liver fat beyond either intervention alone. Genetic proof-of-concept: Kraus et al. (Nature, 2014) used an antisense oligonucleotide to knock down NNMT in mice and reported reduced fat-mass gain, better glucose tolerance, and lower liver triglycerides — the founding paper for the whole NNMT-inhibitor field.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
May support reductions in fat mass while preserving lean muscle in animal models[5][6].
Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3].
Enhanced grip strength observed in aged mice when combined with exercise[7].
Protocol Reference
Protocol reference
Commonly cited research range: 2.5–5 mg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Days 1–2 (Tolerance)
2.5 mg once daily
Days 3+ (Standard)
5 mg once daily
Split option (BID)
2.5 mg twice daily
| Phase | Reference amount | Units / volume |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg once daily | 15 units (0.15 mL) |
| Days 3+ (Standard) | 5 mg once daily | 30 units (0.30 mL) |
| Split option (BID) | 2.5 mg twice daily | 15 units (0.15 mL) |
Titration protocol
- Days 1–2 (tolerance)Start2.5 mg once daily
Once daily.
- Days 3+ (standard)Build5 mg once daily
Once daily; cycle 8–12 weeks on, then 4–6 weeks off.
- Split option (BID)Maintenance2.5 mg twice daily
Two injections per day; rotate injection sites (abdomen, outer thigh, back of upper arm).
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Bring the vial to room temperature — take the vial out of the freezer and let it sit on the counter for 15–20 minutes to prevent condensation when the seal opens.
- 02🧴Wipe the vial top — use a fresh alcohol swab on the rubber stopper of both the 5-Amino-1MQ vial and the BAC water vial.
- 03💉Draw 3 mL bacteriostatic water into a sterile syringe — this 50 mg vial yields 16.7 mg/mL.
- 04💧Add slowly — insert the needle and let the water run down the inside wall of the vial; do not blast it directly onto the powder.
- 05🔄Swirl, do not shake — gently swirl or roll the vial between your hands until the powder dissolves into a clear solution.
- 06🏷️Inspect — the solution should be clear with no cloudy particles; if it looks off, do not use the vial.
- 07❄️Label and refrigerate — write the reconstitution date on the vial; store at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks. Do not refreeze.
- 08💉Important: This guide is for educational purposes only and is not medical advice.
Additional storage notes
Room temperature — Keep in a cool, dry, dark place. Stable up to 12 months at room temperature.
-4 °F (-20 °C) or colder — Best for long storage. Stable up to 24 months.
35.6 to 46.4 °F (2 to 8 °C) — Acceptable for short transit and short holds.
35.6 to 46.4 °F (2 to 8 °C) — Refrigerate. Use within 2 to 4 weeks. Do not refreeze.
Clear after mixing — Cloudy or particulate solution means stop using it.
Clinical Evidence
Clinical evidence
Preclinical studies show reduced fat mass and improved metabolic markers. Increases energy expenditure and NAD+ levels.
Cell-culture (3T3-L1 adipocytes): 5-Amino-1MQ at 30 µM strongly reduced 1-MNA levels in mouse fat cells, confirming NNMT inhibition (Neelakantan et al., Biochemical Pharmacology, 2018). Rodent (diet-induced obesity, 11 days): Subcutaneous 5-Amino-1MQ at roughly 34 mg/kg/day reduced body weight and white adipose mass without changing food intake or lean mass. Rodent (diet-induced obesity, 28 days): Babula et al. (2024) confirmed dose-dependent body-weight and fat-mass reduction over a longer treatment window, with improvements in fatty-liver markers. Rodent (lean diet combination): Sampson et al. (Scientific Reports, 2021) reported that NNMT inhibition plus a lean-diet substitution lowered body weight, fat mass, and liver fat beyond either intervention alone. Genetic proof-of-concept: Kraus et al. (Nature, 2014) used an antisense oligonucleotide to knock down NNMT in mice and reported reduced fat-mass gain, better glucose tolerance, and lower liver triglycerides — the founding paper for the whole NNMT-inhibitor field.
- 015-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme studied in adipocyte and metabolic regulation (mechanistic / in vitro).
- 02In preclinical work, NNMT inhibition with 5-amino-1MQ was associated with reduced fat accumulation and altered metabolic parameters in diet-induced obese mice (animal model; Biochemical Pharmacology, 2018).
- 03Proposed mechanisms involve effects on cellular NAD+ and methylation metabolism in adipose tissue (in vitro / mechanistic).
- 04It is a small molecule, not a peptide, and acts intracellularly rather than on cell-surface receptors (mechanistic).
- 05No human clinical trials are established; the evidence base is preclinical.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to 5-Amino-1MQ.
- 01Nature Medicine (2014) — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity View Sourceet al. (2014)
- 02PMC (2024) — Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions View Sourceet al. (2024)
- 03Frontiers in Pharmacology (2024) — NNMT: a novel therapeutic target for metabolic syndrome View Sourceet al. (2024)
- 04PubMed (2021) — LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study View Sourceet al. (2021)
- 05ResearchGate (2021) — Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice View Sourceet al. (2021)
- 06PMC (2022) — Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice View Sourceet al. (2022)
- 07NMN.com / Scientific Reports — Role of NNMT inhibition in muscle strength: enhanced grip strength with exercise View Source
- 08Swolverine — 5-Amino-1MQ mechanism, benefits, stacking and cycling guide View Source
- 09PMC — Subcutaneous drug injection review: pharmacologic considerations View Source
- 10CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source
- 11CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
- 12NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
- 13Journal of Medicinal Chemistry (ACS) — Bisubstrate inhibitors of NNMT with enhanced activity View Source
- 14PMC — NNMT: a bad actor in fat makes good in liver View Source
- 15Pure Lab Peptides — 5-Amino-1MQ (50 mg) product page (quality and batch documentation) View Source
Observed Effects
Observed effects in cited research
Most commonly reported
- Mild stimulant-like effects (warmth, slight resting heart-rate rise) in the first 1 to 2 weeks.
- Insomnia if dosed in the afternoon or evening — the most preventable observed effect on the list.
- Mild stomach upset with oral capsules in some users.
- Stinging at the injection site with the subcutaneous route, due to the quinolinium chemistry.
- Reduced exercise tolerance during the first weeks of cardiovascular training, per some research community reports.
Theoretical or under-studied
- Liver enzyme changes — community use guides recommend a baseline ALT/AST check and a recheck during long cycles.
- Cancer risk in people with a cancer history, because of NNMT's complex role in tumor biology.
- Long-term effects of repeated cycles have not been mapped in any published study.
- Drug interactions with methyl-donor-sensitive medications are theoretical, not confirmed.
Quality-control risks
- Because 5-Amino-1MQ is sold under research-use-only labels, batch purity and identity depend on the supplier. Capsule products are not regulated as supplements, so dose accuracy varies. Match the certificate of analysis (COA) to the exact lot before any use. Treat poorly documented capsules as the bigger near-term risk, not the compound itself.
Research Considerations
Research considerations
Research compound. Limited human data. Consult healthcare provider.
- Pregnancy and breastfeeding: not studied. Avoid.
- Active cancer or recent cancer history: NNMT plays a complex role in cancer biology. In some tumor types, NNMT activity helps the tumor grow; in others, the picture is less clear. Until human safety data exists, anyone with a cancer history should avoid 5-Amino-1MQ outside formal oncology research.
- Liver disease: liver enzyme monitoring is recommended in community use, and a baseline ALT/AST check is reasonable before starting.
- Children and teenagers: no safety data exists.
- Anyone taking methyl-donor-sensitive medications (some psychiatric drugs, methotrexate, methylated B-vitamin protocols at high doses): NNMT shares the methyl donor SAM, so theoretical interactions exist.
- People with known sleep disorders: the metabolic activation effect can worsen insomnia if dosed late in the day.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| 5-Amino-1MQthis | Inhibits nicotinamide N-methyltransferase (NNMT), increasing NAD+ availability and enhancing mitochondrial metabolism. | oral, subcutaneous | Investigational / RUO |
| Adipotide | A peptidomimetic that targets prohibitin on the vasculature of white adipose tissue and delivers a pro-apoptotic sequence, studied for selective reduction of fat-tissue blood supply. | subcutaneous | Investigational / RUO |
| AICAR | A cell-permeable nucleoside phosphorylated intracellularly to ZMP, an AMP-mimetic that activates AMP-activated protein kinase (AMPK), shifting cells toward oxidative metabolism. | subcutaneous | Investigational / RUO |
| AOD-9604 | Stimulates lipolysis and inhibits lipogenesis. Fragment retains fat-reducing properties without metabolic side effects of full GH. | subcutaneous | Investigational / RUO |
| Cagrilintide | A long-acting acylated amylin analog that activates central amylin (calcitonin-family) receptors to promote satiety and slow gastric emptying. | subcutaneous | Investigational / RUO |
| Ara-290 | An 11-amino-acid non-erythropoietic peptide derived from erythropoietin's helix-B domain that selectively activates the innate repair receptor (an EPOR/CD131 heterocomplex), studied for tissue protection and resolution of inflammation. | subcutaneous | Investigational / RUO |
| BPC-157 | Promotes angiogenesis, accelerates wound healing, and protects organs. Interacts with growth hormone receptors and NO system. | subcutaneous, intramuscular | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small synthetic molecule that blocks an enzyme called NNMT (nicotinamide N-methyltransferase). Researchers study it for fat-cell shrinkage, higher NAD+ levels, and metabolic support — without affecting appetite.
No. 5-Amino-1MQ is a small molecule, not a chain of amino acids. It is often sold alongside research peptides because it fits the same metabolic research space, but chemically it is closer to a small-molecule drug than to peptides like BPC-157 or semaglutide.
No. As of June 2026, 5-Amino-1MQ has no FDA-approved use. It is sold under research-use-only labeling and is not regulated as a dietary supplement either. No human clinical trials have been published.
Research community use most often centers on 100 mg per day oral, taken in the morning. The full range reported is 50 to 150 mg per day, usually starting at 50 mg for the first 1 to 2 weeks and increasing if well tolerated. These numbers come from rodent studies scaled to a human size, not from human clinical trials.
Subcutaneous use is uncommon and dose-limited. A 50 mg vial mixed with 3.0 mL of bacteriostatic water gives about 16.7 mg/mL, and the example subcutaneous range is 2.5 to 5 mg per day. Anything higher than that quickly becomes too much volume for one subQ site, which is why oral capsules are the standard route.
Oral is the standard. 5-Amino-1MQ has good oral absorption based on cell-uptake testing (Neelakantan 2018), and the typical 50 to 150 mg dose is far too large to inject comfortably. The subcutaneous route exists for researchers using a lyophilized vial format, but it is limited to small doses.
The most common reports are mild stimulant-like effects (warmth, slightly higher resting heart rate), insomnia if dosed late in the day, and mild stomach upset with capsules. Injection-site stinging happens with the subQ route. Long-term human safety data does not exist.
Pregnant or breastfeeding people, anyone with active cancer or a recent cancer history, anyone with liver disease, children and teenagers, and anyone with known sleep disorders should avoid 5-Amino-1MQ outside formal research supervision.
Research community reports describe first measurable body composition changes at weeks 4 to 6, with peak effect at weeks 8 to 12. The mechanism is slow because it works by reprogramming fat cells, not by suppressing appetite.
Common research community cycles run 8 to 12 weeks on, followed by 4 to 6 weeks off. The off-period gives baseline NNMT activity a chance to reset before the next cycle.
Some research community protocols combine 5-Amino-1MQ with AOD-9604 (fat oxidation) or with a GLP-1 drug like semaglutide (appetite suppression), since the mechanisms do not overlap. No human study has tested these combinations.
No. This page is an educational research-context reference. 5-Amino-1MQ is not FDA-approved and is not a supplement. Talk to a qualified clinician before considering any use.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.